Nucleic Acid, Nucleoside, or Nucleotide – Page 5

Intellia’s CRISPR Therapy NTLA-2002 Shows 81% Reduction in Hereditary Angioedema Attacks in Phase 2 Study

6 months ago talkbio0Tagged Angioedemas, Hereditary, Clustered Regularly Interspaced Short Palindromic Repeats, Functional, Gene Modification, Intellia, NTLA-2002, Phase 2 Clinical Trials, Swelling attacks

CRISPR therapy, Intellia Therapeutics, NTLA-2002, Hereditary Angioedema (HAE), Gene editing, Phase 2 study, Swelling attacks, Functional cure

Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks

6 months ago talkbio0Tagged Angioedemas, Hereditary, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, gene therapy, Infrequent, Intellia

Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases

Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases

6 months ago talkbio0Tagged AAVS1 gene, Cloning Vectors, Collaboration, Dyno, gene delivery process, gene therapy, LEAP, Neurological diseases, Roche (company), Technology

Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration

Sangamo Therapeutics Fast-Tracks Fabry Gene Therapy with FDA Accelerated Approval Pathway

6 months ago talkbio0Tagged Accelerated, approval pathway, Fabry Disease, gene therapy, Isaralgagene civaparvovec, Sangamo, ST-920, STAAR, United States Food and Drug Administration

Sangamo Therapeutics, Fabry disease, gene therapy, isaralgagene civaparvovec, FDA, accelerated approval pathway, ST-920, STAAR study

Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment

6 months ago talkbio0Tagged Alzheimer 's disease, Antibodies, Bepranemab, Investments, Roche (company), UCB, uridine triacetate

Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment

Gilead and Merck’s Investigational HIV Combo Shows Promising Long-Term Viral Suppression in Phase 2 Trial

6 months ago talkbio0Tagged Co., HIV, islatravir, Lenacapavir, Merck & Co., oral regimen, Phase 2 clinical trial, viral suppression, Weekly

HIV treatment, Weekly oral regimen, Islatravir, Lenacapavir, Viral suppression, Phase 2 clinical trial, Gilead Sciences, Merck & Co.

Eli Lilly and insitro Collaborate on AI-Driven Metabolic Disease Therapies

7 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biotechnology, Drug Discovery, Eli, Eli Lilly, GalNAc, Insitro, Metabolic Diseases, pharmaceutical partnership, RNA, Small Interfering

Eli Lilly, insitro, AI, metabolic diseases, siRNA, GalNAc, drug discovery, biotechnology, pharmaceutical partnership

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

7 months ago talkbio0Tagged Agreement, Antibody Therapy, Aortic Valve Insufficiency, Artificial Intelligence, Drug Development, Eli, Eli Lilly, Insitro, MASLD, Metabolic, Metabolic Diseases, RNA, Small Interfering, steatotic liver disease, strategic

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

RNAi Revolution: Former Alnylam Team Launches $135M siRNA Engineering Startup

7 months ago talkbio0Tagged Alnylam, Cities, Genetic Engineering, RNA Interference, RNA, Small Interfering

RNAi, siRNA, Alnylam, City Therapeutics, John Maraganore, genetic engineering, biotech startup

Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation

7 months ago talkbio0Tagged Chemoradiotherapy, Johnson and Johnson, Malignant neoplasm of urinary bladder, SunRISe-1, TAR 200

Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study